At Week 12 , saroglitazar 2-mg and 4-mg tablets significantly reduced mean plasma triglyceride levels by -45.53.03 % and -46.73.02 % ( meanSE ) , respectively , and the difference was significant ( P < 0.001 ) compared with placebo .
